B-intervention	0	9	Lapatinib
I-intervention	10	14	plus
I-intervention	15	27	capecitabine
O	28	30	in
O	31	36	women
O	37	41	with
O	42	45	HER
O	45	46	-
O	46	47	2
O	47	48	-
O	48	56	positive
O	57	65	advanced
O	66	72	breast
O	73	79	cancer
O	79	80	:
O	81	86	final
O	87	95	survival
O	96	104	analysis
O	105	107	of
O	108	109	a
O	110	115	phase
O	116	119	III
O	120	130	randomized
O	131	136	trial
O	136	137	.

O	138	139	A
O	140	147	planned
O	148	155	interim
O	156	164	analysis
O	165	167	of
O	168	173	study
O	174	183	EGF100151
O	184	192	prompted
O	193	198	early
O	199	210	termination
O	211	213	of
O	214	224	enrollment
O	225	230	based
O	231	233	on
O	234	235	a
O	236	242	longer
O	243	247	time
O	248	250	to
O	251	262	progression
O	263	267	with
O	268	277	lapatinib
O	278	281	and
O	282	294	capecitabine
O	295	299	than
O	300	304	with
O	305	317	capecitabine
O	318	323	alone
O	324	326	in
O	327	335	patients
O	336	340	with
O	341	346	human
O	347	356	epidermal
O	357	363	growth
O	364	370	factor
O	371	379	receptor
O	380	381	(
O	381	384	HER
O	384	385	)
O	385	386	-
O	386	387	2
O	387	388	(
O	388	389	+
O	389	390	)
O	391	401	previously
O	402	409	treated
O	410	418	advanced
O	419	425	breast
O	426	432	cancer
O	433	435	or
O	436	446	metastatic
O	447	453	breast
O	454	460	cancer
O	461	462	(
O	462	465	MBC
O	465	466	)
O	466	467	.

O	468	472	Here
O	472	473	,
O	474	476	we
O	477	483	report
O	484	489	final
O	490	498	analyses
O	499	501	of
O	502	509	overall
O	510	518	survival
O	518	519	.

B-eligibility	520	525	Women
I-eligibility	526	530	with
I-eligibility	531	534	HER
I-eligibility	534	535	-
I-eligibility	535	536	2
I-eligibility	536	537	(
I-eligibility	537	538	+
I-eligibility	538	539	)
I-eligibility	540	543	MBC
I-eligibility	544	547	who
I-eligibility	548	558	progressed
I-eligibility	559	564	after
I-eligibility	565	573	regimens
I-eligibility	574	578	that
I-eligibility	579	587	included
I-eligibility	587	588	,
I-eligibility	589	592	but
I-eligibility	593	597	were
I-eligibility	598	601	not
I-eligibility	602	609	limited
I-eligibility	610	612	to
I-eligibility	612	613	,
I-eligibility	614	628	anthracyclines
I-eligibility	628	629	,
I-eligibility	630	637	taxanes
I-eligibility	637	638	,
I-eligibility	639	642	and
I-eligibility	643	654	trastuzumab
O	654	655	,
O	656	660	were
O	661	671	randomized
O	672	674	to
O	675	684	lapatinib
O	685	686	(
O	686	687	1
O	687	688	,
O	688	691	250
O	692	694	mg
O	694	695	/
O	695	698	day
O	698	699	)
O	700	704	plus
O	705	717	capecitabine
O	718	719	(
O	719	720	2
O	720	721	,
O	721	724	000
O	725	727	mg
O	727	728	/
O	728	729	m
O	729	730	(
O	730	731	2
O	731	732	)
O	732	733	)
O	734	736	or
B-control	737	749	capecitabine
I-control	750	761	monotherapy
O	762	763	(
O	763	764	2
O	764	765	,
O	765	768	500
O	769	771	mg
O	771	772	/
O	772	773	m
O	773	774	(
O	774	775	2
O	775	776	)
O	776	777	)
O	778	780	on
O	781	785	days
O	786	787	1
O	787	788	-
O	788	790	14
O	791	793	of
O	794	795	a
O	796	798	21
O	798	799	-
O	799	802	day
O	803	808	cycle
O	808	809	.

O	810	812	At
O	813	823	enrollment
O	824	835	termination
O	835	836	,
B-total-participants	837	840	399
O	841	849	patients
O	850	854	were
O	855	865	randomized
O	865	866	,
O	867	870	and
O	871	875	nine
O	876	880	were
O	881	886	being
O	887	895	screened
O	896	899	and
O	900	904	were
O	905	912	offered
O	913	924	combination
O	925	934	treatment
O	934	935	.

O	936	938	In
O	939	944	total
O	944	945	,
B-intervention-participants	946	949	207
O	950	953	and
B-control-participants	954	957	201
O	958	966	patients
O	967	971	were
O	972	980	enrolled
O	981	983	to
O	984	995	combination
O	996	1003	therapy
O	1004	1007	and
O	1008	1019	monotherapy
O	1019	1020	,
O	1021	1033	respectively
O	1033	1034	.

O	1035	1041	Thirty
O	1041	1042	-
O	1042	1045	six
O	1046	1054	patients
O	1055	1064	receiving
O	1065	1076	monotherapy
O	1077	1084	crossed
O	1085	1089	over
O	1090	1092	to
O	1093	1104	combination
O	1105	1112	therapy
O	1113	1122	following
O	1123	1133	enrollment
O	1134	1145	termination
O	1145	1146	.

O	1147	1150	The
B-outcome	1151	1157	median
I-outcome	1158	1165	overall
I-outcome	1166	1174	survival
I-outcome	1175	1180	times
O	1181	1185	were
B-iv-cont-median	1186	1188	75
I-iv-cont-median	1188	1189	.
I-iv-cont-median	1189	1190	0
I-iv-cont-median	1191	1196	weeks
O	1197	1200	for
O	1201	1204	the
O	1205	1216	combination
O	1217	1220	arm
O	1221	1224	and
B-cv-cont-median	1225	1227	64
I-cv-cont-median	1227	1228	.
I-cv-cont-median	1228	1229	7
I-cv-cont-median	1230	1235	weeks
O	1236	1239	for
O	1240	1243	the
O	1244	1255	monotherapy
O	1256	1259	arm
O	1260	1261	(
O	1261	1267	hazard
O	1268	1273	ratio
O	1274	1275	[
O	1275	1277	HR
O	1277	1278	]
O	1278	1279	,
O	1280	1281	0
O	1281	1282	.
O	1282	1284	87
O	1284	1285	;
O	1286	1288	95
O	1288	1289	%
O	1290	1300	confidence
O	1301	1309	interval
O	1310	1311	[
O	1311	1313	CI
O	1313	1314	]
O	1314	1315	,
O	1316	1317	0
O	1317	1318	.
O	1318	1320	71
O	1320	1321	-
O	1321	1322	1
O	1322	1323	.
O	1323	1325	08
O	1325	1326	;
O	1327	1328	p
O	1329	1330	=
O	1331	1332	.
O	1332	1335	210
O	1335	1336	)
O	1336	1337	.

O	1338	1339	A
O	1340	1343	Cox
O	1344	1354	regression
O	1355	1363	analysis
O	1364	1375	considering
O	1376	1385	crossover
O	1386	1388	as
O	1389	1390	a
O	1391	1395	time
O	1395	1396	-
O	1396	1405	dependent
O	1406	1415	covariate
O	1416	1425	suggested
O	1426	1427	a
B-iv-bin-percent	1428	1430	20
I-iv-bin-percent	1430	1431	%
B-outcome	1432	1437	lower
I-outcome	1438	1442	risk
I-outcome	1443	1446	for
I-outcome	1447	1452	death
O	1453	1456	for
O	1457	1465	patients
O	1466	1473	treated
O	1474	1478	with
O	1479	1490	combination
O	1491	1498	therapy
O	1499	1500	(
O	1500	1502	HR
O	1502	1503	,
O	1504	1505	0
O	1505	1506	.
O	1506	1508	80
O	1508	1509	;
O	1510	1512	95
O	1512	1513	%
O	1514	1516	CI
O	1516	1517	,
O	1518	1519	0
O	1519	1520	.
O	1520	1522	64
O	1522	1523	-
O	1523	1524	0
O	1524	1525	.
O	1525	1527	99
O	1527	1528	;
O	1529	1530	p
O	1531	1532	=
O	1533	1534	.
O	1534	1537	043
O	1537	1538	)
O	1538	1539	.

O	1540	1543	The
O	1544	1547	low
O	1548	1557	incidence
O	1558	1560	of
O	1561	1568	serious
B-outcome	1569	1576	adverse
I-outcome	1577	1583	events
O	1584	1587	was
O	1588	1598	consistent
O	1599	1603	with
O	1604	1614	previously
O	1615	1623	reported
O	1624	1629	rates
O	1629	1630	.

O	1631	1639	Although
O	1640	1649	premature
O	1650	1660	enrollment
O	1661	1672	termination
O	1673	1676	and
O	1677	1687	subsequent
O	1688	1697	crossover
O	1698	1706	resulted
O	1707	1709	in
O	1710	1722	insufficient
O	1723	1728	power
O	1729	1731	to
O	1732	1738	detect
O	1739	1750	differences
O	1751	1753	in
O	1754	1761	overall
O	1762	1770	survival
O	1770	1771	,
O	1772	1783	exploratory
O	1784	1792	analyses
O	1793	1804	demonstrate
O	1805	1806	a
O	1807	1812	trend
O	1813	1819	toward
O	1820	1821	a
O	1822	1830	survival
O	1831	1840	advantage
O	1841	1845	with
O	1846	1855	lapatinib
O	1856	1860	plus
O	1861	1873	capecitabine
O	1873	1874	.

O	1875	1880	These
O	1881	1885	data
O	1886	1894	continue
O	1895	1897	to
O	1898	1905	support
O	1906	1909	the
O	1910	1918	efficacy
O	1919	1921	of
O	1922	1931	lapatinib
O	1932	1934	in
O	1935	1943	patients
O	1944	1948	with
O	1949	1952	HER
O	1952	1953	-
O	1953	1954	2
O	1954	1955	(
O	1955	1956	+
O	1956	1957	)
O	1958	1961	MBC
O	1961	1962	.
